RecruitMe Clinical Trial
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination with LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Study of LY3321367 Alone or in Combination with LY3300054 in Patients with Solid Tumors
| Sponsor: | Eli Lilly |
| Enrolling: | Male and Female Patients |
| Minimum Age: | 18 years old |
| IRB Number: | AAAR5271 |
| U.S. Government ID: | NCT03099109 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The main purpose of this study is to learn more about the study drug called LY3321367. The study wants to know more about the following: The safety of LY3321367 alone and in combination with another drug called LY3300054 and any side effects you might have Whether LY3321367 is tolerable when taken alone and in combination with LY3300054. How much LY3321367 should be given to patients. Cancer types: breast cancer, lung cancer, gynecologic cancers, skin cancers, melanoma, prostate cancer.
